Article
The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.
All News
Meral K. El Ramahi, MD
Tweet
Inadequate response to MTX, what next?
“Are you forward thinking or are you stuck in the past? Conceptually it is just amazing that you can take a PO tablet as potent as a TNF or IL6 blocker... & the side effects are not so appalling.”—Dr. GreggSilverman. @RheumNow
Meral K. El Ramahi, MD
Tweet
Summary of #ACR20 part C:
- A must see talk was the avacopan story
- IVIG for myositis does work! More than just anecdotal evidence now
- DIET is key to helping improve autoimmune dz!
- low dz activity RA pts should taper off of MTX 1st when also on TNFi @jeffsparks @RheumNow
Olga Petryna
Tweet
@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK. Change in the branch arteries more dynamic than in the aorta https://t.co/2KsZ6o3vtP
Meral K. El Ramahi, MD
Tweet
When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD
Meral K. El Ramahi, MD
Tweet
“We are giving autoimmune diseases to ourselves through bad diet.” — Dr. Gregg Silverman, #ACR20 @RheumNow @drnatalietv
Olga Petryna
Tweet
@RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/sQK4L7Zu76
Meral K. El Ramahi, MD
Tweet
“Avacopan is the little train that could that will eat the antibodies lunch!” - Dr. Gregg Silverman #ACR20 @RheumNow @petermerkel @LCalabreseDO @philseo @AdamJBrownMD
Bella Mehta
Tweet
As #ACR20 is wrapping up, are you are planning to see the conference lectures after the meeting is over? @RheumNow
Richard Conway
Tweet
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Olga Petryna
Tweet
@rheumnow #ACR20 abs1535 retrospective study of SI MRI reveals 20% pts w/out spondyloarthritis have BME on an MRI, predominantly in the antero-middle quadrant. Erosions were seen in 31% of healthy patients and in 61% of patients with spondyloarthritis
Meral K. El Ramahi, MD
Tweet
Summary of #ACR20 part B:
- The future is bright with many trainees producing great research per Dr. Diane Karen
- Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow
Meral K. El Ramahi, MD
Tweet
“Rheumatologists diagnose diseases of inflammation, and we are really good at it!” - Dr. Greg Silverman #ACR20 @RheumNow
Dr. Antoni Chan
Tweet
About half (51%) of patients from the FORWARD registry in the US had at least one telehealth appointment during COVID-19 pandemic and most were satisfied with the appointment @RheumNow #ACR20 Abstr#1962 https://t.co/z38ilD1n8Q
Meral K. El Ramahi, MD
Tweet
Summary of #ACR20 part A:
- HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation
- Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS
@rheumnow
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by @RheumNow & its Faculty.
Robert B Chao, MD
Tweet
Hey Google, does this patient have sacroilitis?
Artificial intelligence model validated for detection of radiographic sacroilitis.
@RheumNow #ACR20 Abs#2018 https://t.co/TDhGKC8ss4
Dr. Antoni Chan
Tweet
What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884
Eric Dein
Tweet
Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow
Eric Dein
Tweet
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
